Skip to main content

IRulya Therapeutics Inc.

corporate_fare Company Profile

IRulya Therapeutics Inc.

IRLA·NASDAQ·Life Sciences·CIK 0001662774

IRulya Therapeutics Inc. is a biotechnology company that, prior to completing its NEAT Phase 3 trial, focused development activities on unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. According to the filing, red blood cells have characteristics that make them an excellent vehicle for drug delivery, potentially including better safety and tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolongation of circulating half-life. The AIDE technology platform is believed to confer several benefits over conventional therapies and can be applied to a broad range of small or large molecule drugs and biologics. The company's lead asset, eDSP, used the AIDE technology to encapsulate DSP into a patient's own red blood cells. In January 2026, IRulya Therapeutics Inc. completed its pivotal Phase 3 NEAT clinical trial evaluating treatment of a rare pediatric neurodegenerative disease, A-T. In the NEAT study, the primary endpoint—measuring change from baseline to the last efficacy visit at month six using the Rescored modified International Cooperative Ataxia Rating Scale (RmICARS) compared to placebo—did not reach statistical significance. Based on the NEAT results, eDSP does not appear to be an effective treatment for A-T, and the company will be unable to continue development of eDSP in this or other therapeutic indications. IRulya Therapeutics Inc. has no other current product candidates and does not have sufficient resources to pursue further research and development activities at this time. It is currently focused on preserving cash while evaluating available strategic alternatives. On February 9, 2026, the company engaged LifeSci Capital as its exclusive financial advisor to assist in restructuring activities and an evaluation of strategic alternatives aimed at maximizing shareholder value.

IRulya Therapeutics Inc. (NASDAQ:IRLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 2 items for IRLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for IRLA spans 10-Q.

Recent high-impact activity:

  • IRulya Q3 Loss Widens to $27.7M on Warrant Mark; $105.2M Cash Funds 12 Months
  • IRulya Posts $27.7M Q3 Loss, Says $105.2M Cash Funds Operations Through 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$83.98M
Diluted EPS
-$1.68
Op. Cash Flow
-$41.42M
Free Cash Flow
-$41.78M
Operating Income
-$58.07M
Cash & Equivalents
$5.81M
Total Debt
$18.03M
Debt / Equity
-0.50×
Shares Outstanding
55.73M sh
Source: 10-K · filed 2026-04-10 · accession 0001193125-26-151364

Short Interest & Short Volume

1.13 days to cover

FINRA reported short interest of 127,816 shares in IRLA as of the October 30, 2026 settlement, a 17.4% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 62.2% of IRLA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)127,816 shares as of October 30, 2026
Change vs prior period▼ 17.4%
Days to cover1.13 at avg daily volume of 112,687
Daily short volume (FINRA facilities)62.2% of 108,452 shares on November 20, 2026
5-day average short volume66.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for IRLA, detected from its recent SEC filings.

1 shelf registration

S-3 Amendment Filed · Resale Registration Details

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

$39.4 -1.20% today
52-week range · as of 2026-11-13 $15.1 – $909.98
Market cap
$432.36M
Volume
200.7K (1.9× avg)
3-mo avg 106K
Live data · 2026-11-22 12:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IRLA - Latest Insights

IRLA
Nov 13, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $39.80
Real-time Price: $39.40 info
Change: -$0.400 (-1%) info
Market Cap: $432.358M info
IRLA
Nov 13, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $39.78
Real-time Price: $39.40 info
Change: -$0.380 (-0.96%) info
Market Cap: $432.358M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets